Concomitant activation of adenylyl cyclase suppresses the opposite influences of CB1 cannabinoid receptor agonists on tyrosine hydroxylase expression

Biochemical Pharmacology

Volumn 77, Issue 2, 2009, Pages 216-227

  Bosier, Barbara ^a   Hermans, Emmanuel ^a   Lambert, Didier M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cell signalling; Forskolin; Functional selectivity; Gene reporter; Tyrosine hydroxylase

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ADENYLATE CYCLASE; CANNABINOID 1 RECEPTOR AGONIST; CRE RECOMBINASE; DEXANABINOL; FORSKOLIN; LUCIFERASE; PERTUSSIS TOXIN; PROTEIN KINASE C; TRANSCRIPTION FACTOR AP 1; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; MOLECULAR CLONING; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; ANIMALS; CANNABINOIDS; CELL LINE, TUMOR; CYCLOHEXANOLS; DNA PRIMERS; ENDOCANNABINOIDS; ENZYME ACTIVATION; EXCITATORY AMINO ACID ANTAGONISTS; FORSKOLIN; GENES, REPORTER; LUCIFERASES; MICE; NEUROBLASTOMA; PERTUSSIS TOXIN; POLYMERASE CHAIN REACTION; RECEPTOR, CANNABINOID, CB1; TETRADECANOYLPHORBOL ACETATE; TETRAHYDROCANNABINOL; TRANSCRIPTION, GENETIC; TRANSFECTION; TYROSINE 3-MONOOXYGENASE;

EID: 57249103358     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.10.010     Document Type: Article

References (56)

1. Kim K.S., Park D.H., Wessel T.C., Song B., Wagner J.A., and Joh T.H. A dual role for the cAMP-dependent protein kinase in tyrosine hydroxylase gene expression. Proc Natl Acad Sci USA 90 (1993) 3471-3475
2. Kim K.S., Lee M.K., Carroll J., and Joh T.H. Both the basal and inducible transcription of the tyrosine hydroxylase gene are dependent upon a cAMP response element. J Biol Chem 268 (1993) 15689-15695
3. Cambi F., Fung B., and Chikaraishi D. 5′ flanking DNA sequences direct cell-specific expression of rat tyrosine hydroxylase. J Neurochem 53 (1989) 1656-1659
4. Chae H.D., Suh B.C., Joh T.H., and Kim K.T. AP1-mediated transcriptional enhancement of the rat tyrosine hydroxylase gene by muscarinic stimulation. J Neurochem 66 (1996) 1264-1272
5. Najimi M., Robert J.J., Mallet J., Rostene W., and Forgez P. Neurotensin induces tyrosine hydroxylase gene activation through nitric oxide and protein kinase C signaling pathways. Mol Pharmacol 62 (2002) 647-653
6. Lim J., Yang C., Hong S.J., and Kim K.S. Regulation of tyrosine hydroxylase gene transcription by the cAMP-signaling pathway: involvement of multiple transcription factors. Mol Cell Biochem 212 (2000) 51-60
7. Piech-Dumas K.M., and Tank A.W. CREB mediates the cAMP-responsiveness of the tyrosine hydroxylase gene: use of an antisense RNA strategy to produce CREB-deficient PC12 cell lines. Brain Res Mol Brain Res 70 (1999) 219-230
8. Thiel G., Al Sarraj J., Vinson C., Stefano L., and Bach K. Role of basic region leucine zipper transcription factors cyclic AMP response element binding protein (CREB), CREB2, activating transcription factor 2 and CAAT/enhancer binding protein alpha in cyclic AMP response element-mediated transcription. J Neurochem 92 (2005) 321-336
9. Tinti C., Yang C., Seo H., Conti B., Kim C., Joh T.H., et al. Structure/function relationship of the cAMP response element in tyrosine hydroxylase gene transcription. J Biol Chem 272 (1997) 19158-19164
10. Rusnak M., and Gainer H. Differential effects of forskolin on tyrosine hydroxylase gene transcription in identified brainstem catecholaminergic neuronal subtypes in organotypic culture. Eur J Neurosci 21 (2005) 889-898
11. Mishra R.R., Adhikary G., Simonson M.S., Cherniack N.S., and Prabhakar N.R. Role of c-fos in hypoxia-induced AP-1 cis-element activity and tyrosine hydroxylase gene expression. Brain Res Mol Brain Res 59 (1998) 74-83
12. Sun B., and Tank A.W. c-Fos is essential for the response of the tyrosine hydroxylase gene to depolarization or phorbol ester. J Neurochem 85 (2003) 1421-1430
13. Page M.E., Oropeza V.C., Sparks S.E., Qian Y., Menko A.S., and Van Bockstaele E.J. Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol Biochem Behav 86 (2007) 162-168
14. Fernandez-Ruiz J., Gomez M., Hernandez M., de Miguel R., and Ramos J.A. Cannabinoids and gene expression during brain development. Neurotox Res 6 (2004) 389-401
15. Bosier B., Tilleux S., Najimi M., Lambert D.M., and Hermans E. Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line. J Neurochem 102 (2007) 1996-2007
16. Bosier B., and Hermans E. Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance. Trends Pharmacol Sci 28 (2007) 438-446
17. Bosier B., Hermans E., and Lambert D. Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor. Br J Pharmacol 155 (2008) 24-33
18. Pierreux C.E., Urso B., De Meyts P., Rousseau G.G., and Lemaigre F.P. Inhibition by insulin of glucocorticoid-induced gene transcription: involvement of the ligand-binding domain of the glucocorticoid receptor and independence from the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. Mol Endocrinol 12 (1998) 1343-1354
19. van der Stelt M., and Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480 (2003) 133-150
20. Lewis-Tuffin L.J., Quinn P.G., and Chikaraishi D.M. Tyrosine hydroxylase transcription depends primarily on cAMP response element activity, regardless of the type of inducing stimulus. Mol Cell Neurosci 25 (2004) 536-547
21. Nakashima A., Ota A., and Sabban E.L. Interactions between Egr1 and AP1 factors in regulation of tyrosine hydroxylase transcription. Brain Res Mol Brain Res 112 (2003) 61-69
22. Papanikolaou N.A., and Sabban E.L. Ability of Egr1 to activate tyrosine hydroxylase transcription in PC12 cells Cross-talk with AP-1 factors. J Biol Chem 275 (2000) 26683-26689
23. Shaulian E., and Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 4 (2002) E131-E136
24. Zhao Q., He Z., Chen N., Cho Y.Y., Zhu F., Lu C., et al. 2-Arachidonoylglycerol stimulates activator protein-1-dependent transcriptional activity and enhances epidermal growth factor-induced cell transformation in JB6 P + cells. J Biol Chem 280 (2005) 26735-26742
25. Maccarrone M., Di Rienzo M., Battista N., Gasperi V., Guerrieri P., Rossi A., et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 278 (2003) 33896-33903
26. Guzman M. Neurons on cannabinoids: dead or alive?. Br J Pharmacol 140 (2003) 439-440
27. Guzman M. Effects on cell viability. Handb Exp Pharmacol (2005) 627-642
28. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266 (1991) 15771-15781
29. Herbert J.M., Augereau J.M., Gleye J., and Maffrand J.P. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 172 (1990) 993-999
30. Gadbois D.M., Hamaguchi J.R., Swank R.A., and Bradbury E.M. Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. Biochem Biophys Res Commun 184 (1992) 80-85
31. Kase H., Iwahashi K., Nakanishi S., Matsuda Y., Yamada K., Takahashi M., et al. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun 142 (1987) 436-440
32. Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 265 (1990) 5267-5272
33. Howlett A.C., Champion-Dorow T.M., McMahon L.L., and Westlake T.M. The cannabinoid receptor: biochemical and cellular properties in neuroblastoma cells. Pharmacol Biochem Behav 40 (1991) 565-569
34. Childers S.R., Pacheco M.A., Bennett B.A., Edwards T.A., Hampson R.E., Mu J., et al. Cannabinoid receptors: G-protein-mediated signal transduction mechanisms. Biochem Soc Symp 59 (1993) 27-50
35. Bash R., Rubovitch V., Gafni M., and Sarne Y. The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. Neurosignals 12 (2003) 39-44
36. McIntosh B.T., Hudson B., Yegorova S., Jollimore C.A., and Kelly M.E. Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. Br J Pharmacol 152 (2007) 1111-1120
37. Georgieva T., Devanathan S., Stropova D., Park C.K., Salamon Z., Tollin G., et al. Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. Eur J Pharmacol 581 (2008) 19-29
38. Glass M., and Northup J.K. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol 56 (1999) 1362-1369
39. Mukhopadhyay S., and Howlett A.C. Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol 67 (2005) 2016-2024
40. Glass M., and Felder C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17 (1997) 5327-5333
41. Calandra B., Portier M., Kerneis A., Delpech M., Carillon C., Le Fur G., et al. Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur J Pharmacol 374 (1999) 445-455
42. Bonhaus D.W., Chang L.K., Kwan J., and Martin G.R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287 (1998) 884-888
43. Perez D.M., and Karnik S.S. Multiple signaling states of G-protein-coupled receptors. Pharmacol Rev 57 (2005) 147-161
44. Yao B.B., Mukherjee S., Fan Y., Garrison T.R., Daza A.V., Grayson G.K., et al. In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?. Br J Pharmacol 149 (2006) 145-154
45. Jentsch J.D., Verrico C.D., Le D., and Roth R.H. Repeated exposure to delta 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat. Neurosci Lett 246 (1998) 169-172
46. Moranta D., Esteban S., and Garcia-Sevilla J.A. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 516-524
47. Joost H.G., Habberfield A.D., Simpson I.A., Laurenza A., and Seamon K.B. Activation of adenylate cyclase and inhibition of glucose transport in rat adipocytes by forskolin analogues: structural determinants for distinct sites of action. Mol Pharmacol 33 (1988) 449-453
48. Hoshi T., Garber S.S., and Aldrich R.W. Effect of forskolin on voltage-gated K + channels is independent of adenylate cyclase activation. Science 240 (1988) 1652-1655
49. Wagoner P.K., and Pallotta B.S. Modulation of acetylcholine receptor desensitization by forskolin is independent of cAMP. Science 240 (1988) 1655-1657
50. Heuschneider G., and Schwartz R.D. cAMP and forskolin decrease gamma-aminobutyric acid-gated chloride flux in rat brain synaptoneurosomes. Proc Natl Acad Sci USA 86 (1989) 2938-2942
51. Sutkowski E.M., Tang W.J., Broome C.W., Robbins J.D., and Seamon K.B. Regulation of forskolin interactions with type I, II, V, and VI adenylyl cyclases by Gs alpha. Biochemistry 33 (1994) 12852-12859
52. Rhee M.H., Bayewitch M., Avidor-Reiss T., Levy R., and Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J Neurochem 71 (1998) 1525-1534
53. Rhee M.H., Nevo I., Avidor-Reiss T., Levy R., and Vogel Z. Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB(1) cannabinoid receptor. Mol Pharmacol 57 (2000) 746-752
54. Albert P.R., and Robillard L. G protein specificity: traffic direction required. Cell Signal 14 (2002) 407-418
55. Ghahremani M.H., Cheng P., Lembo P.M., and Albert P.R. Distinct roles for Galphai2, Galphai3, and Gbeta gamma in modulation offorskolin- or Gs-mediated cAMP accumulation and calcium mobilization by dopamine D2S receptors. J Biol Chem 274 (1999) 9238-9245
56. Majumdar D., Peterson-Ford A., and Uphouse L. 8-OH-DPAT attenuates isoproterenol- but not forskolin-stimulated accumulation of cAMP in mediobasal hypothalamus. Brain Res 1075 (2006) 93-99